Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.

MLA

Lin, Chi, et al. “Phase I Trial of Concurrent Stereotactic Body Radiotherapy and Nelfinavir for Locally Advanced Borderline or Unresectable Pancreatic Adenocarcinoma.” Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, vol. 132, Mar. 2019, pp. 55–62. EBSCOhost, https://doi.org/10.1016/j.radonc.2018.11.002.

APA

Lin, C., Verma, V., Ly, Q. P., Lazenby, A., Sasson, A., Schwarz, J. K., Meza, J. L., Are, C., Li, S., Wang, S., Hahn, S. M., & Grem, J. L. (2019). Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 132, 55–62. https://doi.org/10.1016/j.radonc.2018.11.002

Chicago

Lin, Chi, Vivek Verma, Quan P Ly, Audrey Lazenby, Aaron Sasson, James K Schwarz, Jane L Meza, et al. 2019. “Phase I Trial of Concurrent Stereotactic Body Radiotherapy and Nelfinavir for Locally Advanced Borderline or Unresectable Pancreatic Adenocarcinoma.” Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology 132 (March): 55–62. doi:10.1016/j.radonc.2018.11.002.